FDA Approves REVTORPYK (GEDATOLISIB) for Celcuity Inc.
The FDA has approved REVTORPYK (gedatolisib) under NDA219908 for Celcuity Inc.
Asset / Drug
Drug and asset intelligence for REVTORPYK with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
PI3K Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.